Vericel (NASDAQ:VCEL) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Vericel (NASDAQ:VCEL) from a hold rating to a sell rating in a report issued on Friday.

Several other analysts have also weighed in on the company. BTIG Research lowered their price objective on Vericel from $56.00 to $55.00 and set a buy rating for the company in a report on Monday, July 15th. Canaccord Genuity Group assumed coverage on Vericel in a report on Friday, August 9th. They issued a buy rating and a $57.00 price target on the stock. Canaccord Genuity Group began coverage on shares of Vericel in a report on Friday, August 9th. They set a buy rating and a $57.00 price target for the company. TD Cowen boosted their target price on shares of Vericel from $55.00 to $60.00 and gave the company a buy rating in a research note on Tuesday, August 27th. Finally, Truist Financial increased their price objective on Vericel from $56.00 to $57.00 and gave the stock a buy rating in a report on Tuesday, July 16th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $55.75.

Vericel Trading Down 0.4 %

VCEL opened at $46.37 on Friday. Vericel has a twelve month low of $30.18 and a twelve month high of $54.10. The firm has a market cap of $2.25 billion, a price-to-earnings ratio of -4,637.00 and a beta of 1.67. The company has a fifty day simple moving average of $48.22 and a 200 day simple moving average of $47.44.

Vericel (NASDAQ:VCEL) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). The company had revenue of $52.70 million for the quarter, compared to analyst estimates of $52.59 million. Vericel had a return on equity of 0.35% and a net margin of 0.37%. Vericel’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.11) EPS. On average, analysts forecast that Vericel will post 0.12 earnings per share for the current fiscal year.

Insider Transactions at Vericel

In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $51.40, for a total value of $899,500.00. Following the sale, the chief executive officer now directly owns 220,937 shares in the company, valued at $11,356,161.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CEO Dominick Colangelo sold 17,500 shares of the firm’s stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $51.40, for a total transaction of $899,500.00. Following the completion of the sale, the chief executive officer now directly owns 220,937 shares of the company’s stock, valued at approximately $11,356,161.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Sean C. Flynn sold 15,000 shares of the stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $52.18, for a total value of $782,700.00. Following the completion of the transaction, the insider now owns 707 shares of the company’s stock, valued at approximately $36,891.26. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,045 shares of company stock valued at $1,956,725. Corporate insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Vericel

Several hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC boosted its position in shares of Vericel by 9.7% in the second quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock worth $114,000 after buying an additional 220 shares during the period. MCF Advisors LLC raised its position in Vericel by 86.1% during the first quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 223 shares in the last quarter. Swiss National Bank increased its stake in shares of Vericel by 0.4% during the 1st quarter. Swiss National Bank now owns 89,500 shares of the biotechnology company’s stock worth $4,656,000 after purchasing an additional 400 shares during the last quarter. PFG Investments LLC lifted its stake in shares of Vericel by 6.2% in the 2nd quarter. PFG Investments LLC now owns 6,850 shares of the biotechnology company’s stock valued at $314,000 after purchasing an additional 400 shares during the last quarter. Finally, Arizona State Retirement System increased its position in Vericel by 3.3% during the second quarter. Arizona State Retirement System now owns 12,866 shares of the biotechnology company’s stock worth $590,000 after buying an additional 406 shares during the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.